Cabometyx

What Cabometyx is used for

Renal Cell Carcinoma (RCC) Cabometyx is indicated as monotherapy for advanced renal cell carcinoma as first-line treatment of adult patients with intermediate or poor risk, in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. Hepatocellular carcinoma (HCC)Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.Differentiated thyroid carcinoma (DTC)Cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.Neuroendocrine Tumours (NET)Cabometyx is indicated for the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues.

Approved use, as published by the European Medicines Agency.

Key facts

Brand

Cabometyx

Active substance

cabozantinib

Disease area

Carcinoma, Renal Cell; Carcinomas, Hepatocellular

Medicine group

Antineoplastic agents

ATC code

L01EX07

Marketing authorisation holder

Ipsen Pharma

Authorised in the EU since

2016

Official information

• Cabometyx: European public assessment report (EPAR), product information and package leaflet, on the EMA website

In the USA

Same active substance: Cabometyx, Cometriq